Cargando…
A Placebo-Controlled Trial of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome
BACKGROUND: Smith-Lemli-Opitz syndrome (SLOS) is a multiple malformation/cognitive impairment syndrome characterized by the accumulation of 7-dehydrocholesterol (7DHC), a precursor sterol of cholesterol. Simvastatin, an HMG-CoA reductase inhibitor that crosses the blood-brain-barrier, has been propo...
Autores principales: | Wassif, Christopher A., Kratz, Lisa, Sparks, Susan E., Wheeler, Courtney, Bianconi, Simona, Gropman, Andrea, Calis, Karim A., Kelley, Richard I., Tierney, Elaine, Porter, Forbes D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303568/ https://www.ncbi.nlm.nih.gov/pubmed/27513191 http://dx.doi.org/10.1038/gim.2016.102 |
Ejemplares similares
-
Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update
por: Thurm, Audrey, et al.
Publicado: (2016) -
Smith-Lemli-Opitz-syndrome
por: Gedam, Rachana, et al.
Publicado: (2012) -
Cholesterol deficiency in a mouse model of Smith-Lemli-Opitz syndrome reveals increased mast cell responsiveness
por: Kovarova, Martina, et al.
Publicado: (2006) -
Smith-Lemli-Opitz Syndrome: Bosnian and Herzegovinian Experience
por: Begic, N, et al.
Publicado: (2021) -
Smith-Lemli-Opitz-syndrome: How different is the anesthetic technique?
por: Govindarajan, Srinivasa Raghavan, et al.
Publicado: (2014)